Gabather AB (publ) - Asset Resilience Ratio
Gabather AB (publ) (GABA) has an Asset Resilience Ratio of 82.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gabather AB (publ) financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Gabather AB (publ)'s Asset Resilience Ratio has changed over time. See GABA net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Gabather AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Gabather AB (publ) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.14 Million | 82.06% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.14 Million | 82.06% |
Asset Resilience Insights
- Very High Liquidity: Gabather AB (publ) maintains exceptional liquid asset reserves at 82.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Gabather AB (publ) Industry Peers by Asset Resilience Ratio
Compare Gabather AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Gabather AB (publ) (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Gabather AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 82.06% | Skr3.14 Million ≈ $338.24K |
Skr3.83 Million ≈ $412.17K |
+34.16pp |
| 2024-12-31 | 47.90% | Skr878.00K ≈ $94.49K |
Skr1.83 Million ≈ $197.26K |
+32.76pp |
| 2023-12-31 | 15.14% | Skr1.11 Million ≈ $119.99K |
Skr7.36 Million ≈ $792.48K |
-77.75pp |
| 2022-12-31 | 92.89% | Skr6.27 Million ≈ $674.97K |
Skr6.75 Million ≈ $726.62K |
-3.57pp |
| 2021-12-31 | 96.46% | Skr14.85 Million ≈ $1.60 Million |
Skr15.39 Million ≈ $1.66 Million |
+0.32pp |
| 2020-12-31 | 96.14% | Skr30.92 Million ≈ $3.33 Million |
Skr32.16 Million ≈ $3.46 Million |
-1.32pp |
| 2019-12-31 | 97.46% | Skr44.90 Million ≈ $4.83 Million |
Skr46.07 Million ≈ $4.96 Million |
+5.79pp |
| 2018-12-31 | 91.67% | Skr16.65 Million ≈ $1.79 Million |
Skr18.16 Million ≈ $1.95 Million |
+15.40pp |
| 2017-12-31 | 76.27% | Skr36.74 Million ≈ $3.95 Million |
Skr48.18 Million ≈ $5.18 Million |
-4.14pp |
| 2016-12-31 | 80.41% | Skr27.94 Million ≈ $3.01 Million |
Skr34.75 Million ≈ $3.74 Million |
-- |
About Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more